No business profile yet.
Size YungShin Global (3705.TW) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $472M, the 449th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$58.90 on 18 Nov 2026.
Performance Over six months the shares gained 5.0%, against -14.7% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue fell 5.1% over the last twelve months (peer median +12.5%); the operating margin is 15.1% (peer median 2.5%).
Valuation It trades at 2.0× enterprise value to sales against a peer median of 4.9× (3rd cheapest of 19).
Price implies For today's price to make sense, revenue must grow about -4% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is -5 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 5.7 points above its cost of capital (5.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$7.94B | NT$8.38B | NT$8.03B | NT$7.03B | NT$7.31B |
| Revenue growth | — | +4% | +14% | -4% | — |
| Gross profit | NT$3.41B | NT$3.58B | NT$3.46B | NT$2.91B | NT$3.06B |
| EBITDA | NT$1.48B | NT$1.61B | NT$1.59B | NT$1.22B | NT$1.13B |
| Net income | NT$950M | NT$881M | NT$1.17B | NT$827M | NT$839M |
| Free cash flow | NT$592M | NT$1.01B | NT$1.14B | NT$1.09B | NT$820M |
| Capital expenditure | NT$511M | NT$516M | NT$241M | NT$125M | NT$151M |
| Total debt | NT$1.44B | NT$1.19B | NT$1.23B | NT$1.24B | NT$1.83B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 3705.TW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -5.0% | -2.6% | 9th lowest of 21 |
| 6-month return | +5.0% | -14.7% | 7th highest of 20 |
| Distance from 52-week high | -5.0% | -39.3% | 2nd highest of 21 |
| Revenue growth (TTM) | -5.1% | +12.5% | 5th lowest of 20 |
| Operating margin | 15.1% | 2.5% | 6th highest of 19 |
| EV / Sales | 2.0× | 4.9× | 3rd cheapest of 19 |
| Growth the price implies (Req g, 7 yrs) | -3.8% | 5.9% | 3rd least demanding of 8 |
| Growth delivered (Del g) | +0.7% | +6.3% | 3rd lowest of 8 |
| Hurdle (Req g minus delivered) | -4.6 pp | -0.2 pp | 4th least demanding of 8 |
| ROIC minus cost of capital | +5.7 pp | -5.4 pp | 3rd highest of 17 |
| EV / EBITDA | 10.6× | 24.8× | 2nd cheapest of 4 |
| Net debt / EBITDA | -0.5× | 0.9× | 2nd least indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| YungShin Global 3705.TW | Taiwan | $472M | +5% | -5% | 15% | 2.0× | -3.8% | +0.7% |
| ChengDa PharmaCeuticals 301201.SZ | China | $472M | -47% | +27% | -9% | 4.8× | n/a | n/a |
| Aquestive Therapeutics AQST | United States | $475M | -9% | +13% | -114% | 10.9× | n/a | n/a |
| Handa Pharmaceuticals 6620.TWO | Taiwan | $469M | +45% | -16% | 30% | 16.6× | 24.8% | +126.7% |
| Evolus EOLS | United States | $468M | +7% | +14% | -5% | 1.8× | n/a | n/a |
| Zhejiang Yatai Pharmaceutical 002370.SZ | China | $468M | -32% | -4% | -11% | 8.8× | n/a | n/a |
| SMS Pharmaceuticals SMSPHARMA.NS | India | $477M | +16% | +13% | 16% | 4.9× | n/a | n/a |
| Capricor Therapeutics CAPR | United States | $467M | -70% | -100% | n/a | n/a | n/a | n/a |
| Kwality Pharmaceuticals KPL.NS | India | $467M | +110% | +48% | 22% | 7.2× | n/a | n/a |
| Shanghai Fudan Forward S&T 600624.SS | China | $478M | 0% | -14% | -34% | 6.4× | n/a | n/a |
| Hansa Biopharma HNSA.ST | Sweden | $479M | +39% | +69% | -190% | 14.9× | -4.7% | +105.3% |
| Hainan Shuangcheng Pharmaceuticals 002693.SZ | China | $465M | -28% | +40% | 13% | 10.8× | 44.1% | +1.0% |
| REGENXBIO RGNX | United States | $480M | +22% | -5% | -120% | 3.1× | n/a | n/a |
| BlossomHill Therapeutics BLSM | United States | $464M | n/a | n/a | n/a | n/a | n/a | n/a |
| Shanghai MicuRx Pharmaceutical 688373.SS | China | $481M | -8% | +23% | -61% | 19.0× | n/a | n/a |
| Hefei Lifeon Pharmaceutical 003020.SZ | China | $486M | -21% | -1% | 10% | 2.0× | n/a | n/a |
| Assembly Biosciences ASMB | United States | $458M | -15% | +80% | -32% | 2.2× | n/a | n/a |
| Nanjing Hicin Pharmaceutical 300584.SZ | China | $487M | -29% | +32% | 17% | 4.3× | 3.3% | -1.1% |
| Newland Pharmaceutical 301277.SZ | China | $488M | -22% | +9% | 11% | 3.5× | 8.9% | +9.1% |
| Tong Ren Tang Technologies 1666.HK | Hong Kong | $491M | -19% | -14% | 12% | 0.6× | -17.2% | +6.3% |
| Shandong Wohua Pharmaceutical 002107.SZ | China | $493M | -20% | -4% | 18% | 3.7× | 5.9% | -4.1% |